![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » ASTRAZENECA TO BUY CAMBRIDGE ANTIBODY TECHNOLOGIES
ASTRAZENECA TO BUY CAMBRIDGE ANTIBODY TECHNOLOGIES
May 15, 2006
UK- and Sweden-based AstraZeneca plans to buy Cambridge Antibody Technologies for approximately $1.3 billion, the company reported. AstraZeneca will offer $24.98 per share for Cambridge.
Together, the companies will work to expand AstraZeneca's pipeline of biological therapeutics -- specifically respiratory, anti-inflammatory, neurological, cardiovascular, gastrointestinal and oncology medications.
"It is our intention to both expand and broaden the scope of our discovery and development pipeline and we expect that, by 2010, up to a quarter of our candidates for full scale development will be biological therapeutic agents," said David Brennan, CEO of AstraZeneca.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct